Patents by Inventor Fumitaka KAMACHI

Fumitaka KAMACHI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
    Patent number: 10583129
    Abstract: This invention is directed to prostaglandin E2 receptor 4 (EP4) antagonists useful in the treatment of nonalcoholic steatohepatitis (NASH)-associated liver cancer in a human or animal. The method comprises administering one or more of Compound A, Compound B or Compound C, or pharmaceutically acceptable salts thereof, as the EP4 antagonist(s). The method may include a pharmaceutical composition comprising the EP4 antagonist, and may include one or more other active agents and/or therapies.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: March 10, 2020
    Assignee: AskAt Inc.
    Inventors: Naoko Ohtani, Fumitaka Kamachi, Tze Mun Loo, Shinichi Koizumi, Takako Okumura
  • USE OF EP4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NASH-ASSOCIATED LIVER CANCER
    Publication number: 20190365680
    Abstract: This invention is directed to prostaglandin E2 receptor 4 (EP4) antagonists useful in the treatment of nonalcoholic steatohepatitis (NASH)-associated liver cancer in a human or animal. The method comprises administering one or more of Compound A, Compound B or Compound C, or pharmaceutically acceptable salts thereof, as the EP4 antagonist(s). The method may include a pharmaceutical composition comprising the EP4 antagonist(s), and may include one or more other active agents and/or therapies.
    Type: Application
    Filed: November 2, 2017
    Publication date: December 5, 2019
    Inventors: Naoko OHTANI, Fumitaka KAMACHI, Tze Mun LOO, Shinichi KOIZUMI, Takako OKUMURA
  • USE OF EP4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NASH-ASSOCIATED LIVER CANCER
    Publication number: 20190269663
    Abstract: This invention is directed to prostaglandin E2 receptor 4 (EP4) antagonists useful in the treatment of nonalcoholic steatohepatitis (NASH)-associated liver cancer in a human or animal. The method comprises administering one or more of Compound A, Compound B or Compound C, or pharmaceutically acceptable salts thereof, as the EP4 antagonist(s). The method may include a pharmaceutical composition comprising the EP4 antagonist, and may include one or more other active agents and/or therapies.
    Type: Application
    Filed: May 21, 2019
    Publication date: September 5, 2019
    Inventors: Naoko OHTANI, Fumitaka KAMACHI, Tze Mun LOO, Shinichi KOIZUMI, Takako OKUMURA
  • Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
    Patent number: 10342785
    Abstract: This invention is directed to prostaglandin E2 receptor 4 (EP4) antagonists useful in the treatment of nonalcoholic steatohepatitis (NASH)-associated liver cancer in a human or animal. The method comprises administering one or more of Compound A, Compound B or Compound C, or pharmaceutically acceptable salts thereof, as the EP4 antagonist(s). The method may include a pharmaceutical composition comprising the EP4 antagonist, and may include one or more other active agents and/or therapies.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: July 9, 2019
    Assignee: AskAt Inc.
    Inventors: Naoko Ohtani, Fumitaka Kamachi, Tze Mun Loo, Shinichi Koizumi, Takako Okumura
  • USE OF EP4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NASH-ASSOCIATED LIVER CANCER
    Publication number: 20180125832
    Abstract: This invention is directed to prostaglandin E2 receptor 4 (EP4) antagonists useful in the treatment of nonalcoholic steatohepatitis (NASH)-associated liver cancer in a human or animal. The method comprises administering one or more of Compound A, Compound B or Compound C, or pharmaceutically acceptable salts thereof, as the EP4 antagonist(s). The method may include a pharmaceutical composition comprising the EP4 antagonist, and may include one or more other active agents and/or therapies.
    Type: Application
    Filed: November 4, 2016
    Publication date: May 10, 2018
    Inventors: Naoko OHTANI, Fumitaka KAMACHI, Tze Mun LOO, Shinichi KOIZUMI, Takako OKUMURA